Clinical Trials
44
Trial Phases
5 Phases
Drug Approvals
1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (41 trials with phase data)• Click on a phase to view related trials
A Retrospective Chart Review Study of Patients With Chronic Lung Allograft Dysfunction-Bronchiolitis Obliterans Syndrome (CLAD-BOS) Post Lung Transplantation
- Conditions
- Bronchiolitis Obliterans Syndrome Due to and After Lung Transplantation (Disorder)
- First Posted Date
- 2024-07-16
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Zambon SpA
- Target Recruit Count
- 284
- Registration Number
- NCT06503770
- Locations
- 🇺🇸
Cleveland Clinic Main Campus, Cleveland, Ohio, United States
🇺🇸Baylor Scott and White Health Advanced Lung Disease Specialists, Dallas, Texas, United States
🇧🇪Universitaire Ziekenhuizen Leuven (UZ Leuven) Campus Gasthuisberg, Leuven, Belgium
Phase 1 Three Part SAD, MAD & Cross-Over Study of ZP-059 in Healthy and Asthmatic Subjects
- Conditions
- Allergic Bronchopulmonary Aspergillosis
- Interventions
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2021-11-15
- Lead Sponsor
- Zambon SpA
- Target Recruit Count
- 58
- Registration Number
- NCT04229303
- Locations
- 🇬🇧
Medicines Evaluation Unit Ltd. (MEU), Manchester, United Kingdom
A Safety Study of Liposomal Cyclosporine A to Treat Bronchiolitis After Hematopoietic Transplant (BOSTON-4)
- Conditions
- Bronchiolitis Obliterans Syndrome (BOS)Stem Cell Transplant ComplicationsGVHD, Chronic
- Interventions
- Drug: Liposomal Placebo
- First Posted Date
- 2019-09-27
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- Zambon SpA
- Target Recruit Count
- 6
- Registration Number
- NCT04107675
- Locations
- 🇫🇷
CHU Hôpital Sud, Amiens, France
🇫🇷Centre Hospitalier Universitaire d'Angers, Angers, France
🇫🇷Centre Hospitalier Universitaire Grenoble Alpes - Hopital Albert Michallon, La Tronche, France
Extension Trial on Efficacy / Safety of L-CsA + SoC in Treating BOS in Post Single or Double Lung Transplant (BOSTON-3)
- Conditions
- Bronchiolitis ObliteransObliterative BronchiolitisBronchiolitis Obliterans Syndrome
- Interventions
- Drug: Liposomal Cyclosporine A 5 mgDrug: Liposomal Cyclosporine A 10 mg
- First Posted Date
- 2019-07-31
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- Zambon SpA
- Target Recruit Count
- 262
- Registration Number
- NCT04039347
- Locations
- 🇺🇸
Banner - University Medical Center, Phoenix, Arizona, United States
🇺🇸David Geffen School of Medicine at UCLA, Los Angeles, California, United States
🇺🇸UCSF, San Francisco, California, United States
An Observational Study on Safinamide, Rasagiline and Other Standard of Care in PD
- Conditions
- Parkinson's Disease
- First Posted Date
- 2019-06-21
- Last Posted Date
- 2024-04-11
- Lead Sponsor
- Zambon SpA
- Target Recruit Count
- 1235
- Registration Number
- NCT03994328
- Locations
- 🇩🇪
Praxis Dr. med. Kirsten Hahn, Berlin, Germany
🇮🇹Università degli Studi G. D'Annunzio, Chieti, Italy
🇪🇸Corporacio Sanitaria Parc Tauli, Sabadell, Spain
- Prev
- 1
- 2
- 3
- 4
- 5
- Next
News
NCFB Pipeline Shows Promise with Over 15 Companies Developing New Therapies
• The non-cystic fibrosis bronchiectasis (NCFB) market is experiencing growth due to rising prevalence and increased awareness, leading to early diagnosis and treatment. • Over 15 companies are actively developing more than 15 NCFB drugs, aiming to improve the treatment landscape for this chronic lung condition. • Key players like Insmed, AstraZeneca, and Verona Pharma are advancing promising therapies such as brensocatib, benralizumab and ensifentrine through clinical trials. • Recent clinical trial milestones, including Phase III results for brensocatib and Phase II enrollment for AP-PA02, signal progress in addressing unmet needs in NCFB treatment.